Curagen Corp Watch

EX-4.1

from 8-K 4 pages This Second Supplemental Indenture, Dated as of December 31, 2009 (This “Second Supplemental Indenture”), Is by and Among Curagen Corporation (The “Curagen”), Celldex Therapeutics, Inc. (“Celldex”) and the Bank of New York Mellon (Formerly, the Bank of New York), as Trustee Under the Indenture Referred to Below (The “Trustee”)

12/34/56

EX-4.1

from 8-K 8 pages This Supplemental Indenture, Dated as of September 30, 2009 (This “Supplemental Indenture”), Is by and Among Curagen Corporation (The “Company”), Celldex Therapeutics, Inc. (“Parent”) and the Bank of New York Mellon (Formerly, the Bank of New York), as Trustee Under the Indenture Referred to Below (The “Trustee”)

12/34/56

EX-4.1

from DEFA14A 6 pages Amendment to the Stockholder Rights Agreement

12/34/56

EX-4.1

from 8-K 6 pages Amendment to the Stockholder Rights Agreement

12/34/56

EX-4.1

from 10-Q 23 pages Curagen Corporation Amended and Restated By-Laws

12/34/56

EX-4.5

from 10-K 105 pages Curagen Corporation as Issuer the Bank of New York, as Trustee Up to $120,000,000 Aggregate Principal Amount of 4.0% Convertible Subordinated Notes Due 2011 Indenture Dated as of February 17, 2004

12/34/56

EX-4.4

from 10-K ~50 pages Stockholder Rights Agreement

12/34/56

EX-4.2

from S-3 ~50 pages Exhibit 4.2 - Form of Subordinated Indenture

12/34/56

EX-4.1

from S-3 ~50 pages Exhibit 4.1 - Form of Senior Indenture

12/34/56

EX-4.2

from S-3 ~20 pages Registration Rights Agreement Dated 02/02/2000

12/34/56

EX-4.1

from S-3 >50 pages Indenture Dated 02/02/2000

12/34/56

EX-4.2

from S-1/A 1 page Form of Common Stock Certificate

12/34/56